Sobi's rights issue fully subscribed

NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO
AUSTRALIA, CANADA, JAPAN, HONG KONG, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR THE
UNITED STATES OR IN ANY JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD
BE UNLAWFUL.

Swedish Orphan Biovitrum's (Sobi) rights issue with preferential rights for the
company's shareholders has been fully subscribed and the underwriting
commitments do not need to be utilized. The subscription period of the rights
issue ended on May 26, 2011. Approximately 99.9 per cent of the offered shares
have been subscribed for with subscription rights and an additional 0.1 per cent
have been subscribed for without subscription rights. In total, applications for
non-preferential subscription have been received corresponding to approximately
81% of the total number of new shares. The subscription price was SEK 12 per new
share and Sobi's shareholders were entitled to subscribe for one new share for
each four existing shares held.

The shares that were subscribed for without subscription rights have been
allocated according to the principles outlined in the prospectus that was
published on May 5, 2011. Notification regarding allocation of shares that have
been subscribed for without subscription rights will be distributed to those who
have been allocated shares around June 1, 2011.

The rights issue provides Sobi with proceeds of approximately SEK 637 million
before transaction costs. Pursuant to the rights issue Sobi's share capital will
increase by SEK 29,105,800 to approximately SEK 146,664,000. The number of
shares will increase by 53,045,319 common shares to a total of 267,295,132
shares[1].

The rights issue is expected to be registered with the Swedish Companies
Registration Office around June 8, 2011 and trading in the new shares on NASDAQ
OMX Stockholm is expected to start on June 10, 2011.

--------------------------------------------------------------------------------

[1] Whereof 2,068,534 share of class C that are held by the company.


For additional information, please contact
Åsa Stenqvist, VP Communications and Investor Relations
Telephone: +46 8-697 20 00

About Swedish Orphan Biovitrum (Sobi)
Sobi is a leading European specialty pharmaceutical company. The company is
focused on providing and developing specialty pharmaceuticals for patients with
rare diseases and significant medical needs. The portfolio comprises about 60
marketed products, as well as projects in late clinical phase. Key therapeutic
areas are hematological diseases, autoimmune diseases, hereditary metabolic
disorders and therapeutic oncology. In 2010 Sobi had revenues of SEK 1.9 B and
approximately 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. For more information please visitwww.sobi.com.

The above information has been made public in accordance with the Swedish
Securities Market Act and/or the Financial Instruments Trading Act. The
information was released for public distribution on
June 1, 2011 at 8.30 CET.
IMPORTANT INFORMATION

The information in this press release is not intended for distribution,
publication or public release, directly or indirectly, in or into Australia,
Canada, Hong Kong, Japan, Singapore, South Africa, Switzerland, the United
States or any other jurisdiction where the distribution of this press release
may be unlawful. The distribution of this announcement may be restricted by law
in certain jurisdictions and persons into whose possession any document or other
information referred to herein comes should inform themselves about and observe
any such restriction.

The information in this press release is not an offer to sell or a solicitation
to buy shares. This press release is not a prospectus under the Prospectus
Directive 2003/71/EC. A prospectus has been prepared and published in accordance
with the Prospectus Directive. The Prospectus has also been made available by
the Company. Investors shall not subscribe for securities referred to in this
press release other than on the basis of the information which is included in
such prospectus.

The information in this press release does not constitute or form a part of any
offer or solicitation to purchase or subscribe for securities. The securities
mentioned herein have not been, and will not be, registered under the United
States Securities Act of 1933 (the "Securities Act") or under the securities
laws of any state or other jurisdiction in the United States, and may not be
offered or sold in the United States, except pursuant to an exemption from, or
in a transaction not subject to, the registration requirements of the Securities
Act and in compliance with any applicable securities laws of any state or other
jurisdiction in the United States. There will be no public offer of securities
in the United States.

The information in this press release may not be forwarded or distributed to any
other person and may not be reproduced in any manner whatsoever. Any forwarding,
distribution, reproduction, or disclosure of this information in whole or in
part may be prohibited. Failure to comply with these instructions may result in
a violation of the Securities Act or the applicable laws of other jurisdictions.

This press release may contain forward-looking statements. Words such as
"expect", "believe", "estimate", "plan" and "forecast" in this press release are
intended to indicate forward-looking statements. These forward looking
statements reflect the current expectations on future events of the management
at the time such statements are made, but are made subject to risks and
uncertainties. All these forward-looking statements are based on the
expectations and assumptions of the management and are deemed reasonable but
uncertain and difficult to predict. Actual outcomes and results may differ
significantly from the forward looking statements. The Company does not intend,
nor undertakes, to update any such forward looking statements.